Shanghai Haoyuan Chemexpress Co., Ltd.

Share · CNE1000051J4 (XSHG)

Overview

No Price

Closing Price XSHG 27.01.2026: 84,00 CNY

27.01.2026 07:00

Current Prices from Shanghai Haoyuan Chemexpress Co., Ltd.

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
SSE	688131.SS	CNY	27.01.2026 07:00	84,00 CNY	0,42 CNY +0,50 %

Share Float & Liquidity

Free Float 48,91 %

Shares Float 103,74 M

Shares Outstanding 212,1 M

Company Profile for Shanghai Haoyuan Chemexpress Co., Ltd. Share

Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.

AI Analysis of Shanghai Haoyuan Chemexpress Co., Ltd.

Click any analysis below to get instant AI insights from finAgent

Latest AI Analyses of Shanghai Haoyuan Chemexpress Co., Ltd.

No AI threads available for this company yet.

Company Data

Name Shanghai Haoyuan Chemexpress Co., Ltd.

Company Shanghai Haoyuan Chemexpress Co., Ltd.

Website https://www.chemexpress.cn

Primary Exchange

SSE

ISIN CNE1000051J4

Asset Class Share

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

CEO Baofu Zheng

Market Capitalization 18 Mrd.

Country China

Currency CNY

Employees 3,6 T

Address No. 3 Building, No. 1999, 201203 Shanghai

IPO Date 2021-06-08

Dividends from 'Shanghai Haoyuan Chemexpress Co., Ltd.'

Ex-Date	Dividend per Share
22.10.2025	0,08 CNY

Ticker Symbols

Name	Symbol
SSE	688131.SS

More Shares

Investors who hold Shanghai Haoyuan Chemexpress Co., Ltd. also have the following shares in their portfolio:

EQUINIX 17/26 Bond

ISHARES NASDAQ BIOTECHNOLOGIESLOGY INDEX FUND ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog